Genmab A GMAB
NASDAQ GMAB
$34.74 +0.21 (+0.61%)
At close: Sep 18, 2026 · 4:00 PM EDT

Genmab A (GMAB) Goodwill & Intangibles (2018 - 2026)

Genmab A's (GMAB) quarterly Goodwill & Intangibles came in at $9.2 billion in Q2 2026, up 337.92% on a YoY basis from $2.1 billion in Q2 2025, and down 0.82% quarter-over-quarter from $9.3 billion in Q1 2026.

Analysis

Genmab A (GMAB) Goodwill & Intangibles (2018 - 2026) Analysis & Trends

Genmab A (GMAB) has reported Goodwill & Intangibles for 9 consecutive years, with $9.2 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Goodwill & Intangibles rose 337.92% year-over-year to $9.2 billion; the trailing twelve-month figure through Jun 2026 stood at $9.2 billion (up 337.92% YoY), and the FY2025 full-year result was $9.5 billion, up 6973.13% from the prior year.
  • Goodwill & Intangibles fell to $9.2 billion in Q2 2026 per GMAB's latest filing, from $9.3 billion in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $9.5 billion in Q4 2025 and bottomed at $2.2 million in Q1 2024.
  • Historically, Goodwill & Intangibles has averaged $2.0 billion across 5 years, with a median of $33.3 million in 2022.
  • The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles slumped 85.55% in 2024, then jumped 95125.23% in 2025.
  • Over 5 years, Goodwill & Intangibles stood at $33.3 million in 2022, then soared by 151.26% to $83.7 million in 2023, then plunged by 85.55% to $12.1 million in 2024, then jumped by 78259.74% to $9.5 billion in 2025, then fell by 2.65% to $9.2 billion in 2026.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods registered $9.2 billion, $9.3 billion, and $9.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 Genmab A 2.23 Bn 728.64 Mn 1.07 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9.23 Bn
Mar 31, 2026 9.30 Bn
Dec 31, 2025 9.48 Bn
Sep 30, 2025 2.10 Bn
Jun 30, 2025 2.11 Bn
Mar 31, 2025 2.11 Bn
Dec 31, 2024 12.10 Mn
Sep 30, 2024 1.34 Bn
Jun 30, 2024 1.36 Bn
Mar 31, 2024 2.22 Mn
Dec 31, 2023 83.70 Mn
Sep 30, 2023 10.65 Mn
Jun 30, 2023 12.27 Mn
Mar 31, 2023 12.66 Mn
Jan 1, 2023 21.00 Mn
Dec 31, 2022 33.31 Mn
Sep 30, 2022 19.00 Mn
Jun 30, 2022 22.02 Mn
Mar 31, 2022 25.08 Mn
Dec 31, 2021 26.67 Mn